摘要
药物相互作用,尤其是药代学的相互作用的研究近年来成为热点。吉非罗齐是一个临床常用的降脂药物,而在临床高脂血症合并糖尿病情况较多,所以吉非罗齐与口服降糖药合用后是否有相互作用也应该是临床医生的关注点。本文综述吉非罗齐对临床几种常用口服降糖药的药代学和药效学的影响,及从其机制上予以分析。吉非罗齐通过对CYP2C的抑制作用而明显影响口服降糖药的药代学及药效学,所以在临床上合用时需及时监测血糖的浓度或调整口服降糖药的用量。
Drug interactions,particularly the studies of interaction between pharmacokinetics become a hot spot in recent years.Gemfibrozil is a lipid-lowering drugs commonly used in clinical,and there are many opportunities hyperlipidemia be in diabetes clinical situation,so whether there are interactions between gemfibrozil and oral agents should also be the concern of clinicians.We review the effect of Gemfibrozil to the pharmacokinetics and pharmacodynamics of several commonly used oral hypoglycemic drug,and to analyze its mechanism.Gemfibrozil inhibited CYP2C and significant effect the pharmacokinetics and pharmacodynamics of oral hypoglycemic drug,so monitoring the blood glucose concentrations in time or adjust the dosage of oral hypoglycemic agents when they are combined in clinical is necessary.
出处
《中国临床药理学与治疗学》
CAS
CSCD
2011年第1期116-120,共5页
Chinese Journal of Clinical Pharmacology and Therapeutics